On April 30, 2012, FDA granted tentative approval under expedited review provisions of the President’s Emergency Plan for AIDS Relief, or PEPFAR, for nevirapine tablets 200 mg. The product, manufactured by ScieGen Pharmaceuticals, Inc. of Happauge, NY, is indicated for use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection.
“Tentative approval” means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections. Tentative approval does, however, make the product eligible for purchase outside the United States under the PEPFAR program.
This is a generic version of Viramune tablets 200 mg , manufactured by Boehringer Ingelheim.
As with all generic applications, FDA conducts an on-site inspection of each manufacturing facility, and of the facilities performing the bioequivalence studies, to evaluate the ability of the manufacturer to produce a quality product and to assess the quality of the bioequivalence data supporting the application prior to granting approval or tentative approval to these applications.